A comprehensive post-market review of studies on a probiotic product containing Lactobacillus helveticus R0052 and Lactobacillus rhamnosus R0011
- PMID: 22146691
- DOI: 10.3920/BM2011.0032
A comprehensive post-market review of studies on a probiotic product containing Lactobacillus helveticus R0052 and Lactobacillus rhamnosus R0011
Abstract
The probiotic preparation Lacidofil® has been commercially available in Europe, Asia and North America since 1995. This product is a combination of two strains, Lactobacillus helveticus R0052 and Lactobacillus rhamnosus R0011. The strains have been evaluated for safety, identity and mechanisms of probiotic action in vitro, in animal models and human clinical trials. The strains adhered to human epithelial cells, helped to maintain the barrier function and blocked the adhesion of a number of pathogens, allowing them to be cleared from the intestine. The strains also elicited an anti-inflammatory response by down-regulating IL-1β, IL-8 and TNF-α. In various stress models, the probiotic combination facilitated better coping and outcomes which may be through the maintenance of barrier function and suppressing inflammation. Overall, pre-clinical studies suggest a potential anti-infectious role for the strains and the combination. Clinical studies, primarily in children, have identified Lacidofil as an effective supplement for various gastrointestinal diseases such as antibiotic-associated diarrhoea and acute gastroenteritis. Recent research has also indicated that Lacidofil may be beneficial for individuals with atopic dermatitis or vaginal dysbacteriosis.
Similar articles
-
Effectiveness of Lactobacillus helveticus and Lactobacillus rhamnosus for the management of antibiotic-associated diarrhoea in healthy adults: a randomised, double-blind, placebo-controlled trial.Br J Nutr. 2016 Jul;116(1):94-103. doi: 10.1017/S0007114516001665. Epub 2016 May 12. Br J Nutr. 2016. PMID: 27169634 Clinical Trial.
-
Strain-specific probiotic (Lactobacillus helveticus) inhibition of Campylobacter jejuni invasion of human intestinal epithelial cells.FEMS Microbiol Lett. 2009 Nov;300(1):146-52. doi: 10.1111/j.1574-6968.2009.01781.x. Epub 2009 Sep 4. FEMS Microbiol Lett. 2009. PMID: 19765084
-
Pathogen-Specific Effects of Probiotics in Children With Acute Gastroenteritis Seeking Emergency Care: A Randomized Trial.Clin Infect Dis. 2022 Aug 24;75(1):55-64. doi: 10.1093/cid/ciab876. Clin Infect Dis. 2022. PMID: 34596225 Free PMC article. Clinical Trial.
-
Primary prevention of Clostridium difficile infections with a specific probiotic combining Lactobacillus acidophilus, L. casei, and L. rhamnosus strains: assessing the evidence.J Hosp Infect. 2018 Aug;99(4):443-452. doi: 10.1016/j.jhin.2018.04.017. Epub 2018 Apr 24. J Hosp Infect. 2018. PMID: 29702133 Review.
-
[Administration of probiotic lactobacilli to children with gastrointestinal problems: there is still little evidence].Ned Tijdschr Geneeskd. 2007 Oct 6;151(40):2198-202. Ned Tijdschr Geneeskd. 2007. PMID: 17969569 Review. Dutch.
Cited by
-
Assessment of Probiotic Viability during Cheddar Cheese Manufacture and Ripening Using Propidium Monoazide-PCR Quantification.Front Microbiol. 2012 Oct 4;3:350. doi: 10.3389/fmicb.2012.00350. eCollection 2012. Front Microbiol. 2012. PMID: 23060868 Free PMC article.
-
Probiotic Characteristics and Antimicrobial Potential of a Native Bacillus subtilis Strain Fa17.2 Rescued from Wild Bromelia sp. Flowers.Microorganisms. 2022 Apr 21;10(5):860. doi: 10.3390/microorganisms10050860. Microorganisms. 2022. PMID: 35630306 Free PMC article.
-
Lactobacillus rhamnosus GG modifies the metabolome of pathobionts in gnotobiotic mice.BMC Microbiol. 2021 Jun 3;21(1):165. doi: 10.1186/s12866-021-02178-2. BMC Microbiol. 2021. PMID: 34082713 Free PMC article.
-
Draft genome sequence of probiotic strain Lactobacillus rhamnosus R0011.J Bacteriol. 2012 Feb;194(4):902. doi: 10.1128/JB.06584-11. J Bacteriol. 2012. PMID: 22275100 Free PMC article.
-
Suppression of Intestinal Epithelial Cell Chemokine Production by Lactobacillus rhamnosus R0011 and Lactobacillus helveticus R0389 Is Mediated by Secreted Bioactive Molecules.Front Immunol. 2018 Nov 14;9:2639. doi: 10.3389/fimmu.2018.02639. eCollection 2018. Front Immunol. 2018. PMID: 30524427 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources